Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 in moderate-to-severe plaque psoriasis (Phase I/II)
CTR20190055Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vunakizumab in psoriasis, sponsored by Hengrui Therapeutics. Started Mar 2019; status: completed.
02
Drugs
vunakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20190055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190055.